Shares of Sareum Holdings Plc (LON: SAR) surged 24% after the company announced that it had received US patent protection for its pre-clinical cancer programme.
The biotech company received US patent protection over its SDC-1802 TYK2/JAK1 kinase inhibitor programme, a pre-clinical treatment that targets cancer.
Today’s patent approval is the last step for the company given that it has already received patents from Europe, Japan and China.
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Explore stocks with XTB →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to invest in the stocks making the news?
Go from following the market to investing in it, with access to thousands
of stocks across major UK and international markets.
See available stocks →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Own the stocks you’re reading about
Invest in real shares across the UK, US and other major global markets
through XTB, all from one investment account.
Explore XTB shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
You don’t need to buy a whole share
Fractional shares let you invest from just £1, giving you more control
over how much you put into individual companies.
Explore fractional shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to see how XTB works first?
Explore the platform with an XTB demo account before deciding whether
you want to invest with real money.
Try the XTB demo →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Dr John Reader, the chief scientific officer for the programme, said: “The granting of this patent in the US completes the protection of the intellectual property for our proprietary SDC-1802 Programme across all major markets.”
Adding:
“The board believes that the patent will enhance the value of its TYK2/JAK1 inhibitor programmes and the company’s negotiating position as it continues to engage in discussions with potential licence partners.”
Today’s announcement led Sareum shares to break above the crucial 2.60p resistance level before quickly falling back below the level.
The stock could set up for a rally if the price follows through and rises above the level, or could head into a downtrend if the level holds over the next few days.
Sareum share price
Sareum shares surged 24% to trade at 2.73p having rallied from Wednesday’s closing price of 2.20p.
